New LaunchJun 30, 2026, 09:31 AM
PatentVest Launches Report: FGF21 Reshaping Obesity Market, $10.7B Deals
AI Summary
PatentVest, a division of MDB Capital Holdings, announced the release of its latest PatentVest Pulse report, "The Crossover: How FGF21 Became the Cardiometabolic Layer Beneath GLP-1." The report examines how FGF21 is reshaping obesity therapeutics and intellectual property strategy, highlighting over $10.7 billion in recent acquisitions and licensing activity. It explores how pharmaceutical companies are investing in FGF21 as a complementary approach to GLP-1 therapies for broader cardiometabolic conditions.
Key Highlights
- PatentVest launched "The Crossover" report on FGF21's role in obesity therapeutics.
- Report highlights over $10.7 billion in FGF21-related acquisitions and licensing activity.
- FGF21 is emerging as a strategic cardiometabolic layer beyond GLP-1 therapies.
- Major acquisitions by Novo Nordisk, Roche, and GSK signal confidence in FGF21.
- FGF21 is being developed alongside GLP-1 to address broader cardiometabolic disease.
- The report analyzes clinical programs, IP landscapes, and competitive positioning.
Price Impact
More from MDBH